Abstract
Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 67-81 |
| Number of pages | 15 |
| Journal | Autoimmunity Reviews |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| State | Published - Dec 2009 |
Fingerprint
Keywords
- Opportunistic infection
- Rheumatic diseases
- TNF
- TNF-α inhibitors
- Tuberculosis
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Incidence and nature of infectious disease in patients treated with anti-TNF agents. / Raychaudhuri, Siba P; Nguyen, Caroline T.; Raychaudhuri, Smriti K.; Gershwin, M. Eric.
In: Autoimmunity Reviews, Vol. 9, No. 2, 12.2009, p. 67-81.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Incidence and nature of infectious disease in patients treated with anti-TNF agents
AU - Raychaudhuri, Siba P
AU - Nguyen, Caroline T.
AU - Raychaudhuri, Smriti K.
AU - Gershwin, M. Eric
PY - 2009/12
Y1 - 2009/12
N2 - Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.
AB - Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.
KW - Opportunistic infection
KW - Rheumatic diseases
KW - TNF
KW - TNF-α inhibitors
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=70350566088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350566088&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2009.08.006
DO - 10.1016/j.autrev.2009.08.006
M3 - Article
C2 - 19716440
AN - SCOPUS:70350566088
VL - 9
SP - 67
EP - 81
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 2
ER -